Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Authors
Eggermont, A. M. M.Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, A.
Carlino, M. S.
Sandhu, S. K.
Sarda, S. S. P.
Ascierto, P. A.
Lorigan, Paul C
Grebennik, D.
Ibrahim, N.
Marreaud, S. I.
Suciu, S.
Robert, C.
Affiliation
Quality Of Life Department, European Organisation for Research and Treatment of Cancer, 1200 - BrusselsIssue Date
2022
Metadata
Show full item recordCitation
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson VG, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology. 2022 Sep;33(7):S912-S3. PubMed PMID: WOS:000866211601075.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1089Additional Links
https://dx.doi.org/10.1016/annonc/annonc1089Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1089